Apellis Pharmaceuticals, Inc.

États‑Unis d’Amérique


 
Quantité totale PI 124
Quantité totale incluant filiales 130 (+ 6 pour les filiales)
Rang # Quantité totale PI 10 596
Note d'activité PI 2,9/5.0    112
Rang # Activité PI 6 174
Symbole boursier APLS (nasdaq)
ISIN US03753U1060
Capitalisation 4,400M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

42 14
13 9
39 7
0
 
Dernier brevet 2025 - Compositions and methods for alt...
Premier brevet 2004 - Compositions and methods for enh...
Dernière marque 2024 - SYFOVRE START
Première marque 2019 - APELLIS

Filiales

1 subsidiaries with IP (6 patents, 0 trademarks)

 S'inscrire grtuitement pour accéder à la liste des filiales

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 Invention Dosing regimens and related compositions and methods. In some aspects, the present invention pro...
2024 Invention Compositions and methods for altering complement activation. Compositions and methods for reducin...
P/S Providing information about medication insurance coverage, enrollment in patient benefits program...
Invention Methods of using geographic atrophy lesion characteristics. The present disclosure encompasses me...
Invention Complement inhibition. Among other things, the present disclosure provides technologies for modul...
P/S Organization, production and presentation of exhibitions and displays in the nature of education...
P/S Organization, production and presentation of exhibitions and displays in the nature of education ...
2023 Invention Dosing regimens. In some aspects, the present invention provides cell-reactive compstatin analog...
P/S Organization, production and presentation of exhibitions and displays for educational purposes pe...
Invention Treatment of geographic atrophy. Methods and compositions for treatment of geographic atrophy are...
Invention Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof. In some aspects, th...
Invention Dosing regimens and related compositions and methods. In some aspects, the present invention prov...
2022 Invention Rnas for complement inhibition. RNAs, such as miRNA and siRNA, and their use in treating complem...
P/S Pharmaceutical preparations for the treatment of complement-mediated diseases and disorders.
P/S Pharmaceutical preparations, solely for human use, for the treatment of complement-mediated disea...
Invention Complement inhibitor dosing regimens. Complement is an arm of the innate immune system that plays...
Invention Systems and methods for virtual reality, augmented reality, and mixed reality based visual functi...
Invention Compositions and methods for genome editing the neonatal fc receptor. Provided herein are composi...
Invention Rnas for complement inhibition. RNAs, such as miRNA and siRNA, and their use in treating compleme...
Invention Complement inhibition. Among other things, the present disclosure provides technologies for modu...
Invention Cell-penetrating compstatin analogs and uses thereof. In some aspects, the present invention cel...
P/S Pharmaceutical preparations for the treatment of complement-mediated diseases and disorders
P/S Medical devices, namely, infusion pumps
Invention Genomic editing of complement. Complement activation occurs via three main pathways: the antibod...
Invention Genomic editing of complement. Complement activation occurs via three main pathways: the antibody...
Invention Treatment of complement-mediated disorders. Inappropriate or excessive complement activation is a...
Invention Combination therapy for c3 inhibition. In some aspects, the present invention provides certain c...
Invention Polypeptides for complement inhibition. Proteins comprising a C3 and/or C3b binding polypeptide ...
Invention Polypeptides for complement inhibition. Proteins comprising a C3 and/or C3b binding polypeptide a...
Invention Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods. ...
P/S Pharmaceutical preparations for the treatment of complement-mediated diseases and disorders.
2021 Invention Genomic editing of complement. Methods, systems, and compositions for genomic editing of a gene ...
Invention Genomic editing of complement. Methods, systems, and compositions for genomic editing of a gene e...
Invention Methods of treating eye disorders. Methods of treating eye disorders, e.g., age related macular ...
Invention Methods and compositions for cancer treatment and treatment selection. In some aspects, the disc...
Invention Methods of treating eye disorders. Methods of treating eye disorders, e.g., age related macular d...
Invention Compositions and methods relating to c5l2. In some aspects, provided herein is a method of enhan...
Invention Methods of treating chronic disorders with complement inhibitors. In some aspects, the invention ...
Invention Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof. In some aspects, the...
P/S Recorded and downloadable computer software for use with medical infusion pumps and patient monit...
P/S Educational services, namely, conducting workshops and virtual reality tutorial sessions in the f...
Invention Treatment of paroxysmal nocturnal hemoglobinuria. Methods and compositions for treatment of paro...
Invention Treatment of paroxysmal nocturnal hemoglobinuria. Methods and compositions for treatment of parox...
2020 Invention Cell-penetrating compstatin analogs and uses thereof. In some aspects, the present invention cell...
P/S Providing information about medication insurance coverage, benefits verification, reimbursement, ...
Invention Complement inhibitor dosing regimens. Methods and compositions for inhibiting complement are des...
Invention Viral vector therapy. Methods and compositions for combined therapy with viral vectors and compl...
P/S Pharmaceutical preparations, solely for human use, for the treatment of complement-mediated dise...